Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 7 August 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Strong equipment sales in the hematology field in the Americas, an improved cost ratio resulting from tariff refunds and other factors arising in the Americas during the first half, and optimization of group selling, general and administrative expenses carried out during the first half. The assumed exchange rates for the second half have been revised to ¥155.0 per US dollar, ¥175.0 per euro and ¥23.0 per Chinese yuan, while the full-year rates have been revised to ¥157.1 per US dollar, ¥179.6 per euro and ¥23.3 per Chinese yuan.
| Item | Details |
|---|---|
| Net Sales | 545,000 Millions of yen → 550,000 Millions of yen（+0.9%） |
| Operating profit | 60,000 Millions of yen → 68,500 Millions of yen（+14.2%） |
| Profit attributable to owners of the parent | 37,000 Millions of yen → 40,000 Millions of yen（+8.1%） |
| Net income per share | 60.89 yen/sen → 66.06 yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 7 August 2026 |
| Previous-period results | Net sales: ¥500,006 million; operating profit: ¥51,831 million; profit before tax: ¥49,051 million; profit attributable to owners of the parent: ¥35,457 million; basic earnings per share: ¥56.89 |
| Reason for the revision | Strong equipment sales in the hematology field in the Americas, an improved cost ratio resulting from tariff refunds and other factors arising in the Americas during the first half, and optimization of group selling, general and administrative expenses carried out during the first half. The assumed exchange rates for the second half have been revised to ¥155.0 per US dollar, ¥175.0 per euro and ¥23.0 per Chinese yuan, while the full-year rates have been revised to ¥157.1 per US dollar, ¥179.6 per euro and ¥23.3 per Chinese yuan. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This reflects strong equipment sales in the hematology field in the Americas, an improved cost ratio resulting from tariff refunds and other factors arising in the Americas during the first half, and optimization of group selling, general and administrative expenses carried out during the first half. In addition, the assumed exchange rates for the second half and the full-year rates used to calculate the full-year earnings forecast have been revised.